An expert review, demystifying haematological malignancies

10:00 – 15:00
Friday 21st September 2018
The Royal College of Physicians, London, UK

‘An expert review in demystifying haematological malignancies’, focusing on Chronic Lymphocytic Leukaemia (CLL) and Follicular Lymphoma (FL), is a one day medical education meeting which will bring together a notable faculty of oncology experts from across the UK who will preview the latest advances in research, consider the likely impact on the clinic of tomorrow, and discuss and debate the pertinent issues which are affecting the professional community.



Professor Tariq EnverProfessor Tariq Enver
Director of the UCL Cancer Institute,
London, UK
Dr Anna SchuhDr Anna Schuh
Associate Professor,
Director of Molecular Diagnostics,
Honorary Consultant Haematologist,
University of Oxford, UK

The full programme can be viewed HERE

Who should attend?
This meeting is ideal for:

  • Consultants
  • GPs
  • Pharmacists
  • Nurses
  • Researchers and
  • Scientists

and any healthcare professionals who have an interest in the future shape and direction of FL & CLL research and treatment.

‘An expert review, demystifying haematological malignancies’ (code: 121384) has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 3 category 1 (external) CPD credit(s). Please note, CPD credits obtained through RCP will be accepted by other medical colleges such as the Royal College of Pathologists and the Royal College of Nursing.

When & Where
Friday 21st September 2018, 10:00 – 15:00
The Royal College of Physicians,
11 St Andrews Place,
NW1 4LE.
Map here

The meeting costs are underwritten by Gilead Sciences Ltd. and the event is free of charge for healthcare professionals to attend. Places are strictly limited by room capacity.

To pre-register for the event please indicate your interest and we’ll send you an invitation when full registration opens.

Date of preparation: June 2019

This activity is intended for medical Haematology/Oncology healthcare professionals, scientists and academics involved in the management of, and research into CAR T-cell therapy in patients with high-grade lymphoid malignancies, specifically relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), as well as those with interest in the wider treatment landscape of haematological malignancies. Data on licensed CAR-T products will be presented.